JPRN-UMIN000022422已完成未知
The efficacy of tolvaptan, a vasopressin V2 receptor antagonist, in patients with congestive heart failure and kidney diseases - The efficacy of tolvaptan in patients with congestive heart failure and kidney diseases
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
As compared to baseline, urine volume increased at day 7 in 17 responders, whereas urine volume decreased at day 7 in 13 non-responders. Baseline urine cyclic AMP/plasma AVP ratio distributed between 0.25 and 4.01 with median 1.90. The urine cyclic AMP/plasma AVP ratio was a significant predictor of response to tolvaptan, which was adjusted for 6 potential confounders with a cutoff of 1.24.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients under 20 years of age at time of enrolling 2. Serum Na >=145 mEq/L 3. Patients with difficulty in water intake 4. Anuria 5. Patients with severe liver failure or severe congestive heart failure 6. Others deemed ineligible for this trial by physicians
研究者
相似试验
已完成
1 期
Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle StudyNephrolithiasis, Calcium OxalateNephrolithiasis, Calcium PhosphateNCT02096965Mayo Clinic20
已完成
2 期
Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)NephropathyNCT02078973Regional Hospital Holstebro15
已完成
2 期
Effect of the Aquaretic Tolvaptan on Nitric Oxide SystemAutosomal Dominant Polycystic Kidney DiseaseNCT02527863Regional Hospital Holstebro18
撤回
3 期
A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic HyponatremiaHyponatremiaNCT02442674Otsuka Pharmaceutical Development & Commercialization, Inc.
终止
3 期
Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic HyponatremiaHyponatremiaNCT02012959Otsuka Pharmaceutical Development & Commercialization, Inc.9